Mutation-targeted T cell responses in blood from patients with solid tumors prior to treatment and which evolve with clinical benefit from anti-PD-1 therapies

被引：0

作者：

Yuen, Benjamin ^{[1
]}

Yin, Fangfang ^{[2
]}

An, Duo ^{[1
]}

Quach, Boi ^{[1
]}

Guo, Linlin ^{[1
]}

Tan, Joanne ^{[2
]}

Peng, Songming ^{[1
]}

Pan, Zheng ^{[1
]}

Dalmas, Olivier ^{[1
]}

Bao, Robert ^{[1
]}

Jacoby, Kyle ^{[1
]}

Sennino, Barbara ^{[1
]}

Mandl, Stefanie ^{[1
]}

Walters, Matt ^{[2
]}

Jaen, Juan ^{[2
]}

Franzusoff, Alex ^{[1
]}

Yuen, Benjamin ^{[1
]}

机构：

[1] PACT Pharma, San Francisco, CA USA

[2] Arcus Biosci, Hayward, CA USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2019年 / 7卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P65

引用

页数：2

共 44 条

[31] Safety, durable clinical benefit, and remission resulting from nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase 1 trial in patients with previously treated metastatic renal cell carcinoma (mRCC); long-term patient follow-up
Drake, C. G.
Mcdermott, D. F.
Sznol, M.
Choueiri, T. K.
Kluger, H. M.
Powderly, J. D.
Smith, D. C.
Sankar, V.
Gutierrez, A. A.
Wigginton, J. M.
Gupta, A.
Atkins, M. B.
BJU INTERNATIONAL, 2013, 112 : 9 - 10
[32] Updated efficacy and safety results from the phase 2 study of serplulimab, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors
Jin Li
Qin, Shukui
Zhong, Haijun
Chuan Jin
Chen, Lili
Yuan, Xianglin
Fan, Qingxia
Chen, Kehe
Cao, Peiguo
Xiao, Jianjun
Da Jiang
Tao Zhang
Zhang, Hongyu
Wang, Xicheng
Wei Wang
Lin Han
Wang, Qingyu
Jun Zhu
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[33] A Phase I, dose finding study of BI 754111, an anti-LAG-3 antibody, in combination with BI 754091, an anti-PD-1 antibody, in patients with advanced solid tumors: preliminary results from the microsatellite stable (MSS) metastatic colorectal cancer (mCRC) cohort
Bendell, Johanna
Ulahannan, Susanna V.
Chu, Quincy
Patel, Manish
George, Ben
Landsberg, Renee
Elgadi, Mabrouk
Duffy, Christine
Graeser, Ralph
Tang, Wenbo
Merger, Michael
Ge, Miaomiao
Johnson, Melissa
MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
[34] Evaluation of cytotoxic T cell infiltration and clinical benefit from PD-L1 checkpoint inhibition among PIK3CA mutant microsatellite stable (MSS) metastatic adenocarcinoma patients
Nusrat, Maliha
Tapia, Coya
Call, S. Greg
Hong, David S.
Piha-Paul, Sarina A.
Subbiah, Vivek
Rodon, Jordi
Tsimberidou, Apostolia M.
Adat, Abha
Wang, Yan
Meric-Bernstam, Funda
Overman, Michael J.
Kopetz, Scott
Janku, Filip
CANCER RESEARCH, 2020, 80 (16)
[35] Pharmacokinetics and biomarker analysis from a phase 1/2 open-label study of the anti-GPC3 T-cell engager SAR444200, in patients with advanced solid tumors
Chenard-Poirier, Maxime
Almhanna, Khaldoun
Lim, Darren Wan-Teck
El-Khoueiry, Anthony B.
Samol, Jens
Ryoo, Baek-Yeol
Hong, Jung Yong
Meng, Robin
Abbadessa, Giovanni
Masciari, Serena
Kefsi, Asma
Zhang, Yiding
Guillemin-Paveau, Helene
Pasquier, Benoit
Lepine, Lucie
Dumbrava, Ecaterina Elena
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] Avelumab (MSB0010718C; anti-PD-L1) as a first-line treatment for patients with advanced NSCLC from the JAVELIN Solid Tumor phase 1b trial: Safety, clinical activity, and PD-L1 expression.
Verschraegen, Claire F.
Chen, Franklin
Spigel, David R.
Iannotti, Nicholas
McClay, Edward Francis
Redfern, Charles H.
Bennouna, Jaafar
Taylor, Matthew H.
Kaufman, Howard
Kelly, Karen
Bajars, Marcis
von Heydebreck, Anja
Cuillerot, Jean-Marie
Jerusalem, Guy Heinrich Maria
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[37] Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies.
Li, Weimin
Matakidou, Athena
Ghazoui, Zara
Si, Han
Wildsmith, Sophie
Morsli, Nassim
Mann, Helen
Wrona, Magdalena
de Los Reyes, Melissa
Raja, Rajiv
Barker, Craig
Whiteley, Jessica
Zhang, Qu
Fayette, Jerome
Zandberg, Dan Paul
Mesia, Ricard
Siu, Lillian L.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[38] Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents
Patnaik, Amita
Bang, Yung-Jue
Chung, Hyun C.
de Miguel Luken, Maria Jose
Yap, Timothy A.
Hu, Leijun
Szpurka, Anna M.
Yu, Danni
Chatterjee, Anindya
Nanda, Shivani
Vangerow, Burkhard
Koneru, Mythili
Bendell, Johanna
CANCER RESEARCH, 2018, 78 (13)
[39] ICT01, an anti-butyrophilin 3A targeted mAb activating g9d2 T cells, induces immune remodeling of the tumor microenvironment and clinical responses in combination with pembrolizumab in patients with advanced solid tumors who failed prior checkpoint inhibitor therapy: EVICTION Trial.
Champiat, Stephane
Wermke, Martin
de Bono, Johann
Marabelle, Aurelien
Jungels, Christiane
Vicier, Cecile
Vey, Norbert
List, Catrin
Wetzko, Katrin
Ruhnke, Leo
Garralda, Elena
de Aguiar, Vladimir Galvao
LoRusso, Patricia
Kotecki, Nuria
De Gassart, Aude
Valentin, Emmanuel
Brune, Patrick
Iche, Marina
Leparquier, Celine
Olive, Daniel
Frohna, Paul
CANCER RESEARCH, 2022, 82 (12)
[40] Addition of histamine to IL-2 treatment augments type 1 T cell responses in melanoma patients in vivo: results from a randomized clinical trial of IL-2 with or without histamine (MP 104)
Keilholz, Ulrich
Asemissen, Anne M.
Letsch, Anne
Hellstrand, Kristoffer
Gehlsen, Kurt
Thiel, Eckhardt
Scheibenbogen, Carmen
ANNALS OF ONCOLOGY, 2004, 15 : 204 - 204

← 1 2 3 4 5 →